Literature DB >> 2078408

Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.

J P Moore1, Q J Sattentau, P R Clapham.   

Abstract

We have identified 6 sera containing autoantibodies to CD4 in 174 human immunodeficiency virus-type (HIV-1) positive sera tested in an antigen-capture enzyme-linked immunosorbent assay (ELISA) using sCD4, and none in 34 HIV type 2 sera. These autoantibodies do not bind to cellular CD4, but react with sCD4 to increase its binding in ELISA to monoclonal antibodies and the HIV surface glycoprotein gp120. The effect of CD4 autoantibodies is mimicked by monoclonal antibodies to the third and fourth domains of CD4. The enhanced sCD4 binding to gp120 in ELISA is reflected by a reduction in the concentration of sCD4 required to neutralize HIV-1 and HIV-2 infection in tissue culture when CD4 autoantibodies or the relevant monoclonal antibodies were present.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2078408     DOI: 10.1089/aid.1990.6.1273

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase.

Authors:  Bing Chen; Yifan Cheng; Lesley Calder; Stephen C Harrison; Ellis L Reinherz; John J Skehel; Don C Wiley
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

2.  Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice.

Authors:  Renier Myburgh; Sandra Ivic; Michael S Pepper; Gustavo Gers-Huber; Duo Li; Annette Audigé; Mary-Aude Rochat; Vincent Jaquet; Stephan Regenass; Markus G Manz; Patrick Salmon; Karl-Heinz Krause; Roberto F Speck
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

3.  Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134.

Authors:  Chris K Grant; Elizabeth A Fink; Magnus Sundstrom; Bruce E Torbett; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

4.  Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.

Authors:  J L Spouge
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  The nature of the autoimmune antibody repertoire in human immunodeficiency virus type 1 infection.

Authors:  H J Ditzel; S M Barbas; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.

Authors:  J P Moore; J A McKeating; W A Norton; Q J Sattentau
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  HIV-1 envelope accessible surface and polarity: clade, blood, and brain.

Authors:  Gopichandran Sowmya; Gunasagaran Shamini; Sathyanarayanan Anita; Meena Sakharkar; Venkat Mathura; Hector Rodriguez; Andrew J Levine; Elyse Singer; Deborah Commins; Charurut Somboonwit; John T Sinnott; Harcharan S Sidhu; Ganapathy Rajaseger; Peter Natesan Pushparaj; Pandajarasamme Kangueane; Paul Shapshak
Journal:  Bioinformation       Date:  2011-03-22

8.  Humoral Antibody Responses to HIV Viral Proteins and to CD4 Among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort.

Authors:  Elizabeth Fink; Katherine Fuller; Brian Agan; Edward A Berger; Andrew Saphire; Gerald V Quinnan; John H Elder
Journal:  AIDS Res Hum Retroviruses       Date:  2016-11-21       Impact factor: 2.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.